Steroid Receptor-mediated Cytotoxicity of an Antiestrogen and an Antiprogestin in Breast Cancer Cells

Cancer Research

Volumn 47, Issue 5, 1987, Pages 1441-1448

  Bardon, Sylvie ^a   Vignon, Françoise ^a   Montcourrier, Philippe ^a   Rochefort, Henri ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; 4 HYDROXYTAMOXIFEN H 3; ANTIESTROGEN; ANTIGESTAGEN; ESTRADIOL; ESTROGEN RECEPTOR; MIFEPRISTONE; MIFEPRISTONE H 3; PROMEGESTONE; RADIOISOTOPE; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CELL LINE; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; INTOXICATION; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL SURVIVAL; ESTRADIOL; ESTRENES; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; MIFEPRISTONE; PROGESTATIONAL HORMONES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN;

EID: 0023125219     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sutherland, R. L., and Jordan, V. C. (eds). Non Steroidal Antiestrogens. New York: Academic Press, Inc., 1981.
2. Katzenellenbogen, B. S., Miller, M. A., Mullick, A., and Sheen, Y. Y. Antiestrogen action in breast cancer cell: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res. Treat., 5:231-243, 1985.
3. Lippman, M. E., Bolan, G., and Huff, K. The effect of estrogens on hormone responsive human breast cancer in long term tissue culture. Cancer Res., 36: 4595-4601, 1976.
4. Furr, B. J., Patterson, J. S., Richardson, D. N., Slater, S. R., and Wakeling, A. E. Tamoxifen. In: Golbert, M. E. (ed.), Pharmacological and Biochemical Properties of Drug Substances, Vol. 2, pp. 355–399. Washington, DC: American Pharmacological Association, 1979.
5. Rochefort, H., Bardon, S., Chalbos, D., and Vignon, F. Steroidal and non steroidal antiestrogens in breast cancer cells in culture. J. Steroid Biochem., 20:105-110, 1984.
6. Rochefort, H., and Borgna, J. L. Differences between oestrogen receptor activation by oestrogen and antiestrogen. Nature (Lond.), 292: 257–259, 1981.
7. Westley, B., May, F. E. B., Brown, A. M. C., Krust, A., Chambon, P., Lippman, M. E., and Rochefort, H. Effects of antiestrogens on the estrogen regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. J. Biol. Chem., 259: 10030–10035, 1984.
8. Sutherland, R. L., Green, M. D., Hall, R. E., Reddel, R. P., and Taylor, I. W. Tamoxifen induces accumulation of MCF7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur. J. Cancer Clin. Oncol., 19: 615-622, 1983.
9. Osborne, C. K., Boldt, D. H., Clark, G. M., and Trent, J. M. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res., 43:3583-3585, 1983.
10. Sutherland, R. L., Hall, R. E., and Taylor, I. W. Cell proliferation kinetics of MCF7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res., 43: 3998–4006, 1983.
11. Bardon, S., Vignon, F., Derocq, D., and Rochefort, H. The antiproliferative effect of tamoxifen in breast cancer cells: role of the estrogen receptor. Mol. Cell. Endocrinol., 35:89-96, 1984.
12. Sutherland, R. L., Murphy, L. C., San Foo, M., Green, M. D., and Why-bourne, A. M. High affinity antiestrogen binding site distinct from the estrogen receptor. Nature (Lond.), 288:273-275, 1980.
13. Chalbos, D., and Rochefort, H. Dual effects of the progestin R5020 on proteins released by the T47D human breast cancer cells. J. Biol. Chem., 259:1231-1238, 1984.
14. Bardon, S., Vignon, F., Chalbos, D., and Rochefort, H. RU 486, a progestin glucocorticoid and antagonist inhibits the growth of breast cancer cells via the progesterone receptor. J. Clin. Endocrinol. Metab., 60:692-697.
15. Horwitz, K. B. The antiprogestin RU 38 486: receptor mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47D$$ human breast cancer cells. Endocrinology, 116:2236-2245, 1985.
16. Soule, H. D., Vazquez, J., Lang, A., Albert, S., and Brennan, M. A. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer. Inst., 51:1409-1413, 1973.
17. Lasfargues, E. Y., and Ozzello, L. Cultivation of human breast carcinomas. J. Natl. Cancer. Inst., 21: 1131–1147, 1958.
18. Cailleau, R., Young, R., Olive, M., and Reeves, W. J. Breast tumor cell lines from pleural effusions. J. Natl. Cancer. Inst., 53:661-674, 1974.
19. Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., and Brenner, H. J. Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J. Cancer, 15:659-670, 1979.
20. Westley, B., and Rochefort, H. A secreted glycoprotein induced by estrogen in human breast cancer cell line. Cell, 20: 353-362, 1980.
21. Kissane, J. M., and Robins, E. The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system. J. Biol. Chem., 233:184-188, 1958.
22. Williams, J. R., Little, J. B., and Shipley, W. U. Association of mammalian cell death with a specific endonucleolytic degradation of DNA. Nature (Lond.), 252:754-756, 1974.
23. Bidlack, J. M., and Lockshin, R. A. Evolution of lactate dehydrogenase isoenzymes during programmed cell death. Comp. Biochem. Physiol., 55: 161-166, 1976.
24. Salmon, S. E., Hamburger, A. W., Soehnlen, B., Dune, B. G. M., Alberts, D. S., and Moon, T. E. N. Engl. J. Med., 298: 1321-1327, 1978.
25. Karnovsky, M. A formaldehyde-glutaraldehyde fixative of high osmolality for use in electron microscopy. J. Cell. Biol., 27: 137-138, 1965.
26. Coezy, E., Borgna, J. L., and Rochefort, H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and cell growth inhibition. Cancer. Res., 42:317-323, 1982.
27. Chalbos, D., Vignon, F., Keydar, I., and Rochefort, H. Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J. Clin. Endocrinol. Metab., 55:276-283, 1982.
28. Vignon, F., Capony, F., Chambon, M., Freiss, G., Garcia, M., and Rochefort, H. Autocrine growth stimulation of the MCF7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology, 118:1537-1545, 1986.
29. Mercier, L., Thompson, E. B., and Simons, S. S., Jr. Dissociation of steroid binding to receptors and steroid induction of biological activity in a glucocorticoid responsive cell. Endocrinology, 112:601-609, 1983.
30. Vignon, F., Bardon, S., Chalbos, D., and Rochefort, H. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J. Clin. Endocrinol. Metab., 56: 1124-1130, 1983.
31. Wyllie, A. H. Cell death: a new classification separating apoptosis from necrosis. In: I. D. Bowen and R. A. Lockshin (eds.), Cell Death in Biology and Pathology, pp. 9–34. New York: Chapman and Hall, 1981.
32. Berthois, Y., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. Proc. Natl. Acad. Sci. USA, 83:2496-2500, 1986.
33. Chalbos, D., and Rochefort, H. A 250 kilodalton cellular protein is induced by progestins in two human breast cancer cell lines MCF7 and T47D. Biochem. Biophys. Res. Commun., 121:421-427, 1984.
34. Wyllie, A. H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (Lond.), 284:555-556, 1980.
35. Osborne, C. K., Hobbs, K., and Clark, G. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res., 45: 584-590, 1985.
36. Daniel, P., Gaskell, S. J., Bishop, H., Campbel, C., and Nicholson, R. I. Determination of tamoxifen and biologically active metabolites in human breast tumors and plasma. Eur. J. Cancer., 17:1183-1189, 1981.
37. Cech, P., Block, J. B., Cone, L. A., and Stone, R. Tumor lysis syndrome after tamoxifen flare. N. Engl. J. Med., 315:263-264, 1986.
38. Romieu, G., Maudelonde, T., Ulmann, A., Pujol, H., Grenier, J., Cavalié, G., Khalaf, S., and Rochefort, H. The antiprogestin RU486 in advanced breast cancer preliminary clinical trial. Bulletin du Cancer, in press, 1987.